Qiagen has registered an impressive increase in its value, surpassing the expectations of its shareholders. The supervisory council and management board have approved 'unanimously' the agreement, considering it a better strategy for their upcoming development phase under private ownership. Jonathan M. Pratt, CEO of Qiagen, emphasized especially the greater operational freedom expected with the delisting, which could lead to moving resources more quickly towards opportunities that are more interesting and aligned with their long-term strategic approach.

Rusckowski, chairman of the Supervisory Board, commented: 'The operation offers shareholders convincing value and positions Qiagen for its upcoming development phase under private ownership.' The close is expected around mid-2027 and is subject to regulatory approvals. Additionally, within what is referred to as 'post-closing measures', it states that 'all Qiagen shareholders who have not subscribed to the offer will receive an equal distribution in cash based on the offer price after taxes'.

Conclusione, "l'importo netto percepito da questi azionisti potrebbe risultare inferiore a quello che avrebbero ottenuto se avessero aderito", spiega la società, che in ogni caso dovrebbe procedere al delisting da Frankfurt e New York. Le due società lavorano principalmente sull'esperimento QuantiFeron per la tubercolosi latente, svolto su piattaforme automatiche Liaison di Diasorin. Questa acquisto rappresenta un passo significativo per Qiagen nella sua strada verso la propria prossima fase di sviluppo sotto proprietà privata, dove l'azienda può muoversi più rapidamente e avere maggior libertà nell'indirizzare le risorse verso opportunità più interessanti e coerenti con la sua strategia di lungo termine. L'effetto positivo dell'altezza del Dax 40 è stato notevole, ma il movimento di Qiagen è stato sufficiente a contrapporsi.

The acquisition by Eqt Private Equity has led to an increase in Quid's valuation compared to its previous ones, allowing the company to reach new challenges and development opportunities. After evaluating standalone prospects and discussing alternatives with industrial and financial counterparties, the supervision council and management board of Quid approved the agreement unanimously.

Jonathan M.

Pratt, CEO of Qiagen, has emphasized above all the greater operational freedom expected with the delisting: 'Under private ownership, we can move more quickly and have greater flexibility in directing resources towards opportunities that are more interesting and consistent with our long-term strategy.' The company is preparing further advances in its upcoming phase of development under private ownership, which could lead to significant new results and growth opportunities. The Qiagen operation was seen as an important step for its next phase of development under private ownership, where the enterprise can operate more rapidly and have greater freedom to direct resources towards more interesting and aligned opportunities with its long-term strategy.